FrancophonIA/ELRC3.0 huggingface dataset:
English: The long-term (24 months) clinical safety and efficacy of Lucentis in patients with visual impairment due to macular oedema secondary to RVO were assessed in the BRIGHTER (BRVO) and CRYSTAL (CRVO) studies.
Danish: Den langsigtede (24 måneder) kliniske sikkerhed og effekt af Lucentis hos patienter med synsnedsættelse grundet makulaødem som følge af RVO blev vurderet i BRIGHTER (BRVO) og CRYSTAL (CRVO) studierne.
English: In both studies, the improvement of vision was accompanied by a continuous and significant reduction in the macular oedema as measured by central retinal thickness.
Danish: Forbedringen af synet var i begge studier ledsaget af en vedvarende og signifikant reduktion i det makulære ødem, målt ved den centrale retinale tykkelse.
English: What Lucentis contains - The active substance is ranibizumab.
Danish: Lucentis indeholder: - Aktivt stof: ranibizumab.
English: Post-inflammatory retinochoroidopathy 6.5 Central serous chorioretinopathy Idiopathic chorioretinopathy Miscellaneous aetiologies a a encompasses different aetiologies of low frequency of occurrence not included in the other subgroups
Danish: Post-inflammatorisk korioretinopati Central serøs korioretinopati Idiopatisk korioretinopati Diverse ætiologier a a omfatter forskellige ætiologier med lav hyppighed, som ikke er inkluderet i andre undergrupper
English: Monitoring for disease activity may include clinical examination, functional testing or imaging techniques (e.g. optical coherence tomography or fluorescein angiography).
Danish: Monitorering for sygdomsaktivitet kan inkludere klinisk undersøgelse, funktionstest eller billeddannende teknikker (f.eks. optisk kohærenstomografi eller fluorescensangiografi).
English: Gain of ≥15 letters in visual acuity (%)
Danish: Gevinst på ≥15 bogstaver i synsskarphed (%)
English: Snap off (do not turn or twist) the syringe cap (see Figure 2).
Danish: Knæk sprøjte-hætten af (må ikke drejes eller skrues) (se figur 2).
English: In the phase II study D2201 (RESOLVE), 151 patients were treated with ranibizumab (6 mg/ml, n=51, 10 mg/ml, n=51) or sham (n=49) by monthly intravitreal injections.
Danish: I fase II-studiet D2201 (RESOLVE) blev 151 patienter behandlet med ranibizumab (6 mg/ml, n=51; 10 mg/ml, n=51) eller sham (n=49) som månedlige intravitreale injektioner.
English: Do not use the product if the packaging is damaged.
Danish: Anvend ikke præparatet, hvis pakningen er beskadiget.
English: The safety and efficacy of Lucentis in children and adolescents below 18 years of age for indications other than retinopathy of prematurity have not been established.
Danish: Lucentis' sikkerhed og virkning hos børn og unge under 18 år for andre indikationer end præmatur retinopati, er ikke klarlagt.
English: Granulomatous inflammatory changes were noted in the optic disc of some eyes.
Danish: I nogle øjne blev granulomatøse inflammatoriske forandringer bemærket i synsnervepapillen.
English: Verteporfin PDT (n=143)
Danish: VerteporfinPDT (n=143)
English: The safety of Lucentis 0.2 mg was studied in a 6-month clinical trial (RAINBOW), which included 73 preterm infants with ROP treated with ranibizumab 0.2 mg (see section 5.1).
Danish: Sikkerheden af Lucentis 0,2 mg blev undersøgt i et 6 måneders klinisk forsøg (RAINBOW), som inkluderede 73 præmature spædbørn med ROP behandlet med ranibizumab 0,2 mg (se pkt.
English: In patients with CRVO (CRUISE and extension study HORIZON): Subjects treated with sham in the first 6 months who subsequently received ranibizumab did not achieve comparable gains in VA by Month 24 (~6 letters) compared to subjects treated with ranibizumab from study start (~12 letters).
Danish: Hos patienter med CRVO (CRUISE og forlængelsesstudiet HORIZON): Patienter, der blev behandlet med sham de første 6 måneder, og som derefter fik ranibizumab, opnåede ikke tilsvarende forbedringer i VA ved måned 24 (~6 bogstaver) som patienter der blev behandlet med ranibizumab fra start (~12 bogstaver).
English: Mean change in visual acuity (letters) (SD)
Danish: Middelændring i synsskarphed (bogstaver) (SD)
English: All components are for single use only.
Danish: Alle komponenter er udelukkende til engangsbrug.
English: Rhegmatogenous retinal detachment or macular holes in adults
Danish: Rhegmatogen nethindeløsning eller maculært hul hos voksne
English: Table 5 Outcomes at Month 12 in study D2301 (RESTORE) and at Month 36 in study D2301-E1 (RESTORE Extension)
Danish: Tabel 5 Resultater ved måned 12 i studie D2301 (RESTORE) og ved måned 36 i studie D2301-E1 (RESTORE Extension)
English: The excess volume should be expelled prior to injection.
Danish: Overskydende volumen skal fjernes inden injektion.
English: Transient increases in intraocular pressure (IOP) have been seen within 60 minutes of injection of Lucentis.
Danish: Der er set forbigående stigning i det intraokulære tryk (IOP) inden for 60 minutter efter injektion af Lucentis.
English: In pregnant monkeys, intravitreal ranibizumab treatment resulting in maximal systemic exposures 0.9-7-fold a worst case clinical exposure did not elicit developmental toxicity or teratogenicity, and had no effect on weight or structure of the placenta, although, based on its pharmacological effect ranibizumab should be regarded as potentially teratogenic and embryo-/foetotoxic.
Danish: Intravitreal ranibizumab-behandling, resulterende i maksimal systemisk eksponering i størrelsesordnen 0,9-7 gange den værst tænkelige kliniske eksponering, fremkaldte ingen udviklingstoksicitet eller teratogenicitet hos drægtige aber og havde ingen effekt på vægt eller struktur af placenta.
English: In adults transient increases in intraocular pressure (IOP) have been seen within 60 minutes of injection of Lucentis.
Danish: Hos voksne er der set forbigående stigning i det intraokulære tryk (IOP) inden for 60 minutter efter injektion af Lucentis.
English: Figure 1 Mean change in visual acuity from baseline to Month 24 in study FVF2598g (MARINA) and study FVF2587g (ANCHOR)
Danish: Figur 1 Middelændring i synsskarphed fra udgangsværdi til måned 24 i studie FVF2598g (MARINA) og studie FVF2587g (ANCHOR)
English: Eye disorders Very common
Danish: Øjne Meget almindelig
English: • The treatment of visual impairment due to choroidal neovascularisation (CNV)
Danish: • Behandling af synsnedsættelse grundet koroidal neovaskularisation (CNV)
English: Excess volume to be expelled.
Danish: Overskydende volumen skal presses ud.
English: - The other ingredients are α,α-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections.
Danish: - Øvrige indholdsstoffer: α,α-trehalosedihydrat; histidinhydrochlorid, monohydrat; histidin; polysorbat 20; vand til injektionsvæsker.
English: Note: The dose must be set to 0.05 ml.
Danish: Bemærk: Dosis skal indstilles til 0,05 ml.
English: In the pivotal study G2301 (MINERVA), five adolescent patients aged 12 to 17 years with visual impairment secondary to CNV received open-label treatment with ranibizumab 0.5 mg at baseline followed by an individualised treatment regimen as for the adult population.
Danish: I pivotalstudiet G2301 (MINERVA) fik fem unge patienter i alderen 12 til 17 år med synsnedsættelse grundet CNV åben behandling med 0,5 mg ranibizumab ved baseline efterfulgt af det samme individualiserede behandlingsregime som for den voksne population.
English: The side effects associated with the administration of Lucentis are either due to the medicine itself or the injection procedure and mostly affect the eye.
Danish: Bivirkningerne, der er forbundet med indgivelsen af Lucentis, skyldes enten medicinen eller injektionsproceduren og påvirker for det meste øjet.
English: Systemic adverse events including non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors.
Danish: Systemiske bivirkninger, herunder ikke-okulære blødninger og arterielle tromboemboliske hændelser, er blevet rapporteret efter intravitreal injektion af VEGF-hæmmere.
English: Patients with renal impairment: No formal studies have been conducted to examine the pharmacokinetics of Lucentis in patients with renal impairment.
Danish: Patienter med nyreinsufficiens: Der er ikke udført formelle studier til undersøgelse af farmakokinetikken af Lucentis hos patienter med nyreinsufficiens.
English: Children and adolescents (below 18 years of age) The use of Lucentis in children and adolescents has not been established and is therefore not recommended.
Danish: Børn og unge (under 18 år) Lucentis er ikke blevet undersøgt hos børn og unge og anbefales derfor ikke.
English: The long-term safety profile of ranibizumab observed in the 24-month studies is consistent with the known Lucentis safety profile.
Danish: Langtidssikkerhedsprofilen for ranibizumab, observeret i 24-månedersstudierne, er i overensstemmelse med den kendte Lucentis sikkerhedsprofil.
English: Package leaflet: Information for guardians of babies born prematurely
Danish: Indlægsseddel: Information til omsorgsgivere til for tidligt fødte småbørn
English: In wet AMD, the clinical safety and efficacy of Lucentis have been assessed in three randomised, double-masked, sham- or active-controlled studies of 24 months duration in patients with neovascular AMD.
Danish: Den kliniske sikkerhed og effekt af Lucentis ved våd AMD er blevet vurderet i tre randomiserede, dobbeltblinde, sham- eller aktivt kontrollerede studier af 24 måneders varighed hos patienter med neovaskulær AMD.
English: The mean average change in BCVA from Month 1 to Month 12 compared to baseline was +7.8 (±7.72) letters in the pooled ranibizumab-treated patients (n=102), compared to -0.1 (±9.77) letters for sham-treated patients; and the mean change in BCVA at Month 12 from baseline was 10.3 (±9.1) letters compared to -1.4 (±14.2) letters, respectively (p<0.0001 for the treatment difference).
Danish: Den gennemsnitlige middelændring i BCVA fra måned 1 til måned 12 i forhold til baseline var +7,8 (±7,72) bogstaver hos de ranibizumab-behandlede patienter (n=102) sammenlignet med -0,1 (±9,77) bogstaver hos de patienter, der fik sham, og gennemsnitsændringen i BCVA ved måned 12 fra baseline var henholdsvis 10,3 (±9,1) bogstaver og -1,4 (±14,2) bogstaver (p<0,0001 for behandlingsforskellen).
English: Available data in adolescent patients aged 12 to 17 years with visual impairment due to CNV are described in section 5.1.
Danish: De foreliggende data for unge patienter i alderen 12 til 17 år med synsnedsættelse grundet CNV er beskrevet i pkt.
English: The key outcomes from RADIANCE are summarised in Table 2 and Figure 2.
Danish: Hovedresultaterne fra RADIANCE er opsummeret i Tabel 2 og Figur 2.
English: No carcinogenicity or mutagenicity data are available.
Danish: karcinogenicitet eller mutagenicitet.
English: Treatment of visual impairment due to DME
Danish: Behandling af synsnedsættelse grundet DME
English: The usual dose of an injection is 0.02 ml (which contains 0.2 mg of active substance).
Danish: Den sædvanlige dosis af en injektion er 0,02 ml (som indeholder 0,2 mg af det aktive stof).
English: Talk to your baby's doctor before your baby is given Lucentis.
Danish: Kontakt dit barns læge før dit barn får Lucentis.
English: The safety and efficacy of Lucentis in children and adolescents below 18 years of age have not been established.
Danish: Lucentis' sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt.
English: Non-visual side effects include: Anxiety, nausea.
Danish: Bivirkninger uden for øjet omfatter: Angst, kvalme.
English: To expel the air bubble along with the excess medicinal product, slowly push the plunger until the edge below the dome of the rubber stopper is aligned with the black dosing line on the syringe (equivalent to 0.05 ml, i.e., 0.5 mg ranibizumab).
Danish: For at fjerne luftbobler sammen med det overskydende lægemiddel trykkes stemplet forsigtigt ind, til kanten under gummistopperens runding er på linje med den sorte doseringslinje på sprøjten (dette svarer til 0,05 ml, dvs. 0,5 mg ranibizumab).
English: For the adjunctive use of verteporfin photodynamic therapy (PDT) and Lucentis in wet AMD and PM, see section 5.1.
Danish: For supplerende anvendelse af fotodynamisk terapi (PDT) med verteporfin og Lucentis ved våd AMD og PM, se pkt.
English: Adequate anaesthesia and a broad-spectrum topical microbicide to disinfect the periocular skin, eyelid and ocular surface should be administered prior to the injection, in accordance with local practice.
Danish: Hensigtsmæssig anæstesi og et bredspektret topisk mikrobicid til at desinficere periokulær hud, øjenlåg og okulær overflade skal administreres før injektionen i henhold til lokal praksis.
English: The most common side effects in babies born prematurely are described below:
Danish: De mest almindelige bivirkninger hos for tidligt fødte småbørn er beskrevet nedenfor:
English: (letters)
Danish: (bogstaver)
English: Do not use the pre-filled syringe if the solution is discoloured, cloudy or contains particles.
Danish: Den fyldte injektionssprøjte må ikke anvendes, hvis injektionsvæsken er misfarvet, uklar eller indeholder partikler.
English: BRIGHTER was a 3-arm randomised active-controlled study that compared 0.5 mg ranibizumab given as monotherapy or in combination with adjunctive laser photocoagulation to laser photocoagulation alone.
Danish: BRIGHTER var et 3armet randomiseret, aktivt kontrolleret studie, der sammenlignede 0,5 mg ranibizumab, givet som monoterapi eller i kombination med supplerende laserbehandling, med laserbehandling alene.
English: If you are considering stopping Lucentis treatment, please go to your next appointment and discuss this with your doctor.
Danish: Hvis du holder op med at få behandling med Lucentis Hvis du overvejer at holde op med Lucentis-behandlingen, bedes du komme til din næste aftale og drøfte det med din læge.
English: This swelling can be caused by diabetes (a disease called diabetic macular oedema (DME)) or by the blockage of retinal veins of the retina (a disease called retinal vein occlusion (RVO)).
Danish: Denne opsvulmen kan forårsages af sukkersyge (sygdommen kaldes så diabetisk maculaødem (DME)) eller ved blokering af vener i nethinden (sygdommen kaldes så retinal veneokklusion (RVO)).
English: In preterm infants treatment of retinopathy of prematurity (ROP) is initiated with a single injection per eye and may be given bilaterally on the same day.
Danish: Ved behandling af præmatur retinopati (ROP) hos præmature spædbørn, initieres behandlingen med en enkelt injektion per øje, og kan gives i begge øjne samme dag.
English: Single dose for adults: 0.5 mg/0.05 ml.
Danish: Enkeltdosis til voksne: 0,5 mg/0,05 ml.
English: The usual dose of an injection is 0.05 ml (which contains 0.5 mg of active substance).
Danish: Den sædvanlige dosis af en injektion er 0,05 ml (som indeholder 0,5 mg af det aktive stof).
English: In this study, 225 patients were randomised in a 1:1:1 ratio to receive intravitreal ranibizumab 0.2 mg (n=74), 0.1 mg (n=77), or laser therapy (n=74).
Danish: I dette studie blev 225 patienter randomiseret i en 1:1:1-ratio til at modtage intravitreal ranubizumab 0,2 mg (n=74), 0,1 mg (n=77) eller laserbehandling (n=74).
English: Month 1 to Month 24 (SD)
Danish: BCVA fra måned 1 til måned 24 (SD)
English: BABIES BORN PREMATURELY
Danish: FOR TIDLIGT FØDTE SMÅBØRN
English: The most frequently reported non-ocular adverse reactions are headache, nasopharyngitis and arthralgia.
Danish: De hyppigst rapporterede non-okulære bivirkninger er hovedpine, nasofaryngitis og artralgi.
English: If patients are being treated according to a treat-and-extend regimen, once maximum visual acuity is achieved and/or there are no signs of disease activity, the treatment intervals can be extended stepwise until signs of disease activity or visual impairment recur.
Danish: Hvis patienterne behandles efter et treat-and-extend-regime, kan behandlingsintervallerne, når der er opnået maksimal synsskarphed, og/eller der ikke er tegn på sygdomsaktivitet, øges trinvist, indtil der igen opstår tegn på sygdomsaktivitet eller synsnedsættelse.
English: CRYSTAL was a single-arm study with 0.5 mg ranibizumab monotherapy.
Danish: CRYSTAL var et enkeltarmsstudie med 0,5 mg ranibizumab som monoterapi.
English: Patients gaining ≥15 letters from baseline or reaching 84 letters at Month 2
Danish: Patienter med forbedring ≥15 fra baseline, eller som nåede 84 bogstaver ved måned 2
English: Patient-reported benefits were observed with ranibizumab treatment arms over vPDT (p-value <0.05) in terms of improvement in the composite score and several subscales (general vision, near activities, mental health and dependency) of the NEI VFQ-25.
Danish: Der blev observeret patientrapporterede fordele i de 2 behandlingsarme med ranibizumab i forhold til vPDT (p<0,05) i form af forbedring i sammenlagt pointscore og adskillige underskalaer (generelt syn, nærsyn, mental sundhed og selvhjulpenhed) i NEI VFQ-25.
English: The estimated difference between ranibizumab and laser was 27.4% (95% CI: [18.9, 35.9]).
Danish: Den estimerede forskel mellem ranibizumab og laser var 27,4 % (95 % CI [18,9; 35,9]).
English: - If your baby has an infection in or around the eye. - If your baby has pain or redness (severe intraocular inflammation) in the eye.
Danish: - Hvis dit barn har smerter eller rødme (svær intraokulær inflammation) i øjet.
English: After 6 months, patients in the sham-control arms switched to 0.5 mg ranibizumab.
Danish: Efter 6 måneder blev patienterne i sham-armen skiftet til 0,5 mg ranibizumab.
English: An analysis of year 2 data from Protocol S demonstrated that 42.3% (n=80) of eyes in the ranibizumab-treated group had ≥2-step improvement in DRSS from baseline compared with 23.1% (n=46) of eyes in the PRP group.
Danish: En analyse af år 2 data fra Protokol S viste, at 42,3 % (n=80) af øjnene i den ranibizumab-behandlede gruppe havde ≥2-trins forbedring i DRSS i forhold til baseline sammenlignet med 23,1 % (n=46) af øjnene i PRP-gruppen.
English: Group I Ranibizumab 0.5 mg “vision stability” (n=105)
Danish: Gruppe I ranibizumab 0,5 mg “synsstabilitet” (n=105)
English: Most patients (78%) in the clinical study received one injection per eye.
Danish: I det kliniske forsøg modtog de fleste patienter (78 %) en injektion per øje.
English: BCVA improved from baseline to Month 12 in all five patients, ranging from 5 to 38 letters (mean of 16.6 letters).
Danish: BCVA var forbedret hos alle fem patienter i et interval fra 5 til 38 bogstaver (gennemsnitligt 16,6 bogstaver) i forhold til baseline ved måned 12.
English: Intraocular pressure increased # Adverse reactions were defined as adverse events (in at least 0.5 percentage points of patients) which occurred at a higher rate (at least 2 percentage points) in patients receiving treatment with Lucentis 0.5 mg than in those receiving control treatment (sham or verteporfin PDT).
Danish: Bivirkninger blev defineret som hændelser (i mindst 0,5 procentpoint af patienter) der forekom ved en højere frekvens (mindst 2 procentpoint) hos patienter der fik behandling med Lucentis 0,5 mg i forhold til de patienter, der fik kontrolbehandling (sham eller Verteporfin PDT) * Kun set hos DME-populationen
English: Non-ocular adverse reactions reported in more than one patient treated with ranibizumab 0.2 mg were nasopharyngitis, anaemia, cough, urinary tract infection and allergic reactions.
Danish: De non-okulære bivirkninger, som blev rapporteret for flere end én patient behandlet med ranibizumab 0,2 mg, var nasofaryngitis, anæmi, hoste, urinvejsinfektion og allergiske reaktioner.
English: In excess, VEGF-A causes abnormal blood vessel growth and swelling in the eye which can lead to impairment of vision in diseases like AMD, DME, PDR, RVO, PM and CNV.
Danish: Når VEGF-A er i overskud i øjet, forårsager det en unormal vækst af blodårer og opsvulmen i øjet, der kan medføre synsnedsættelse ved sygdomme som AMD, DME, PDR, RVO, PM og CNV.
English: In BRIGHTER, ranibizumab 0.5 mg with adjunctive laser therapy demonstrated non-inferiority versus ranibizumab monotherapy from baseline to Month 24 (95% CI -2.8, 1.4).
Danish: I BRIGHTER blev der demonstreret non-inferioritet af ranibizumab 0,5 mg med supplerende laserbehandling versus ranibizumab monoterapi fra baseline til måned 24 (95 % CI: -2,8; 1,4).
English: Upon opening of the sealed tray, proceed under aseptic conditions.
Danish: Ved åbning af den forseglede bakke fortsættes under aseptiske betingelser.
English: In total up to three injections per eye may be administered within six months of treatment initiation if there are signs of disease activity.
Danish: Indenfor 6 måneder fra opstart af behandling må der i alt administreres op til tre injektioner per øje, hvis der er tegn på sygdomsaktivitet.
English: After 6 months, subjects in the laser arm could receive 0.5 mg ranibizumab.
Danish: Efter 6 måneder kunne patienter i laser-armen få behandling med 0,5 mg ranibizumab.
English: Occasionally, an infection in the internal portion of the eye, pain or redness (inflammation), detachment or tear of one of the layers in the back of the eye (retinal detachment or tear and retinal pigment epithelial detachment or tear), or clouding of the lens (cataract) may occur after Lucentis treatment.
Danish: Lejlighedsvist kan en infektion i den indre del af øjet, smerter eller rødme (inflammation), løsning eller rift i et af lagene bagest i øjet (nethindeløsning eller -rift og løsning eller rift i nethindepigmentepitel) eller uklarhed af linsen (katarakt) forekomme efter behandling med Lucentis.
English: (letters) (SD) Gain of ≥15 letters in BCVA at Month 24 (%) Mean number of injections (SD) (Months 0-23)
Danish: (bogstaver) (SD) Forbedring på ≥15 bogstaver i BCVA ved måned 24 (%) Gennemsnitlig antal af injektioner (SD) (måned 0-23)
English: In study FVF2598g (MARINA), 716 patients with minimally classic or occult with no classic lesions were randomised in a 1:1:1 ratio to receive monthly injections of Lucentis 0.3 mg, Lucentis 0.5 mg or sham.
Danish: I studie FVF2598g (MARINA) blev 716 patienter med minimalt klassiske eller okkulte og ingen klassiske læsioner randomiseret i forholdet 1:1:1 til at få månedlige injektioner af Lucentis 0,3 mg, Lucentis 0,5 mg eller sham.
English: Single dose of 0.5 mg/0.05 ml.
Danish: Enkeltdosis af 0,5 mg/0,05 ml.
English: Talk to your doctor before you are given Lucentis.
Danish: Kontakt lægen før du får Lucentis.
English: The estimated difference between ranibizumab and laser was 29.9% (95% CI: [20.0, 39.7]).
Danish: Den estimerede forskel mellem ranibizumab og laser var 29,9 % (95 % CI: [20,0, 39,7]).
English: The long-term safety profile of ranibizumab observed in the 24-month extension study is consistent with the known Lucentis safety profile.
Danish: Langtidssikkerhedsprofilen for ranibizumab, der blev observeret i den 24 måneder lange studieudvidelse, stemte overens med den kendte sikkerhedsprofil for Lucentis.
English: The improvement of vision was accompanied by a stabilisation or reduction in central subfield thickness over the 12-month period.
Danish: Forbedringen af synet blev ledsaget af en stabilisering eller reduktion i central retinal tykkelse over 12-måneders-perioden.
English: Laser therapy (N=74)
Danish: Laserbehandling (n=74)
English: In patients with PM, there are limited data on the effect of Lucentis in patients who have previously undergone unsuccessful verteporfin photodynamic therapy (vPDT) treatment.
Danish: Der er begrænsede data vedrørende effekten af Lucentis hos patienter med PM, der tidligere har fået fotodynamisk terapi med verteporfin (vPDT) uden succes.
English: Mean change in visual acuity at Month 6
Danish: Gennemsnitlig ændring i synsskarphed ved måned 6
English: Inject slowly until the rubber stopper reaches the bottom of the syringe to deliver the volume of 0.05 ml.
Danish: Injicér injektionsvæsken langsomt, indtil gummistopperen når bunden af sprøjten, for at injicere injektionsvoluminet på 0,05 ml.
English: Remove syringe cap
Danish: Fjern sprøjtehætten
English: Rhegmatogenous retinal detachment or macular holes
Danish: Rhegmatogen nethindeløsning eller maculært hul
English: How to prepare and administer Lucentis
Danish: Tilberedning og administration af Lucentis